AbbVie (NYSE: ABBV) reported Q4 EPS of $2.16, $0.10 better than the analyst estimate of $2.06. Revenue for the quarter came in at $15.1 billion versus the consensus estimate of $14.82 billion.

GUIDANCE:

AbbVie sees FY2025 EPS of $12.12-$12.32, versus the consensus of $12.13.

For earnings history and earnings-related data on AbbVie (ABBV) click here.